Morgan Stanley Portfolio holdings
Morgan Stanley, founded in 1935 by Henry Sturgis Morgan and Harold Stanley as a spin-off from J.P. Morgan & Co., is a leading global financial services firm headquartered in New York City. Initially focused on investment banking, it has evolved into a diversified powerhouse offering wealth management, institutional securities, and asset management services, catering to corporations, governments, institutions, and high-net-worth individuals. With a strong presence in mergers and acquisitions, underwriting, and trading, Morgan Stanley manages billions in assets and is known for its sophisticated financial advisory services. The firm has adapted to modern markets by expanding its digital offerings and wealth management division, notably through its 2020 acquisition of E*TRADE, solidifying its position as a Wall Street titan.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$2.77B |
| 2 |
McKesson
MCK
|
+$2.38B |
| 3 |
SPCX
SpaceX
SPCX
|
+$2.3B |
| 4 |
HONA
Honeywell Aerospace
HONA
|
+$2.05B |
| 5 |
Amazon
AMZN
|
+$1.37B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$5.96B |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$3.11B |
| 3 |
Honeywell
HON
|
+$1.96B |
| 4 |
Salesforce
CRM
|
+$1.47B |
| 5 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$775M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 26.02% |
| 2 | Technology | 24.63% |
| 3 | Financials | 9.78% |
| 4 | Healthcare | 7.32% |
| 5 | Industrials | 7.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
INTZ
8201
Intrusion
INTZ
$16.2M
| $2 | ﹤0.01% |
2
-7,962
| -100% | -$6.29K |
2024 Q1
9 quarters
|
|
8202
Lexaria Bioscience
LEXX
$6.99M
| – | – |
0
| – | – |
2025 Q4
2 quarters
|
|
8203
Marygold Companies
MGLD
$87.4M
| $2 | ﹤0.01% |
1
| – | – |
2024 Q3
7 quarters
|
|
|
MOGU
8204
MOGU Inc
MOGU
$18.3M
| $2 | ﹤0.01% |
1
| – | – |
2021 Q2
20 quarters
|
|
8205
Marker Therapeutics
MRKR
$16.2M
| $2 | ﹤0.01% |
2
| – | – |
2016 Q4
38 quarters
|
|
|
NVVE
8206
DELISTED
Nuvve Holding Corp
NVVE
| – | – |
0
| – | – |
2020 Q4
22 quarters
|
|
8207
PharmaCyte Biotech
PMCB
$4.34M
| $2 | ﹤0.01% |
2
+1
| +100% | +$1 |
2021 Q3
19 quarters
|
|
8208
SiNtx Technologies
SINT
$14.1M
| $2 | ﹤0.01% |
1
-17
| -94% | -$39 |
2020 Q4
22 quarters
|
|
|
AACG
8209
ATA Creativity
AACG
$29.6M
| $1 | ﹤0.01% |
1
| – | – |
2025 Q1
5 quarters
|
|
|
CHGA
8210
Change Agents Corp
CHGA
$2.26M
| – | – |
-1,380
| Closed | -$10.7K | – |
|
|
BNBX
8211
DELISTED
BNB PLUS CORP
BNBX
| $1 | ﹤0.01% |
3
| – | – |
2024 Q4
6 quarters
|
|
8212
CollPlant Biotechnologies
CLGN
$6.64M
| – | – |
0
| – | – |
2026 Q1
1 quarter
|
|
8213
Fathom Holdings
FTHM
$7.27M
| $1 | ﹤0.01% |
1
-5,500
| -100% | -$4.31K |
2020 Q3
23 quarters
|
|
8214
Inuvo
INUV
$8.51M
| $1 | ﹤0.01% |
1
| – | – |
2019 Q3
27 quarters
|
|
|
JOBY.WS
8215
DELISTED
Joby Aviation Warrants
JOBY.WS
| $1 | ﹤0.01% |
3
| – | – |
2021 Q3
19 quarters
|
|
|
RDHL
8216
Redhill Biopharma
RDHL
$4.79M
| $1 | ﹤0.01% |
1
| – | – |
2017 Q2
36 quarters
|
|
8217
Arcadia Biosciences
RKDA
$637K
| $1 | ﹤0.01% |
2
| – | – |
2018 Q2
32 quarters
|
|
8218
TOMI Environmental Solutions
TOMZ
$13.1M
| – | – |
0
| – | – |
2025 Q4
2 quarters
|
|
|
BTTC
8219
Black Titan Corp
BTTC
$6.52M
| $1 | ﹤0.01% |
1
-1
| -50% | -$1 |
2025 Q4
2 quarters
|
|
|
ACLX
8220
DELISTED
Arcellx
ACLX
| – | – |
-925,813
| Closed | -$106M | – |
|
|
ADFI
8221
DELISTED
Anfield Dynamic Fixed Income ETF
ADFI
| – | – |
-526
| Closed | -$4.47K | – |
|
8222
Adaptiv Select ETF
ADPV
$177M
| – | – |
-1
| Closed | -$43 | – |
|
|
ADTX
8223
DELISTED
ADITXT INC
ADTX
| – | – |
-296
| Closed | -$7.83K | – |
|
|
ADXN
8224
Addex Therapeutics
ADXN
$5.64M
| – | – |
-301
| Closed | -$1.89K | – |
|
8225
Anfield US Equity Sector Rotation ETF
AESR
$249M
| – | – |
-397
| Closed | -$6.64K | – |
|
Similar funds
Morgan Stanley's Q2 2026 Portfolio in Review
As of Q2 2026, Morgan Stanley held 8,715 positions worth $1.89T, up 14% from $1.66T the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Morgan Stanley's Q2 2026 filing shows 425 new, 3,807 increased, 3,215 reduced and 303 closed positions. Its largest new stake was SpaceX: 13,532,773 shares worth $2.31B. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $5.96B.
By sector, the portfolio is most concentrated in Miscellaneous at 26% of assets, down from 27% a quarter earlier, followed by Technology and Financials.
- Morgan Stanley's largest Q2 2026 buy was SpaceX: 13,532,773 shares worth $2.31B.
- Morgan Stanley added most to NVIDIA in Q2 2026, an estimated $2.77B increase.
- Morgan Stanley's biggest Q2 2026 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $5.96B.
- Morgan Stanley fully exited Apellis Pharmaceuticals in Q2 2026, selling an estimated $404M.
- Morgan Stanley's ten largest holdings make up 21% of its $1.89T portfolio in Q2 2026.
- Morgan Stanley opened 425 new positions and closed 303 in Q2 2026.
- Morgan Stanley's portfolio value rose 14% quarter-over-quarter to $1.89T.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.